undamentalytics Newsletter
Sign in

Lipocine Inc. income statement

In fiscal 2025, Lipocine Inc. reported revenue of $2.0m, down 82.3% on the year before, operating income of −$10.4m (a -524.7% margin) and net income of −$9.6m, or −$1.69 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue8000000161−31122
Research and development25811671089107910
General and administrative241010568545544
Operating income4−11−19−21−11−13−183−12−18−1−10−13
Interest expense—————1000————
Income before tax4−11−19−21−12−13−21−1−11−160−10−12
Income tax0−00000000000—
Net income4−11−19−21−12−13−21−1−11−160−10−12
Diluted EPS$14.45−$24.48−$1.04−$1.05−$0.55−$0.50−$0.38−$0.01−$2.15−$3.14—−$1.69−$1.75
Diluted shares (average)——1m1m1m2m3m5m5m5m5m6m7m
EBITDA4−11−19−21−11−13−183−12−18−1−10−13

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: LPCN vs NTRBLPCN vs SXTCLPCN vs SXTPLPCN vs SCNX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Lipocine Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lipocine Inc.